PDUFA Pulse

PDUFA catalysts, FDA approvals, biotech pipeline analysis

📊 Newsletter: Every Mon (link below)
📄 Free FDA Catalyst Guide for subscribers

[PDUFA Pulse @PDUFA_Pulse]

📌Hello, quick reminder that Biotech Dealmaker Brief starts Monday in private beta.

sample brief - https://t.co/C57YQK6GuY

This is the PDUFA Pulse-adjacent product I’m testing for people who price, source, structure, or evaluate biotech transactions. The format is a weekly BD committee prep memo.

The goal is to answer: When a biotech event resolves, what changes for deal pricing?

A sample issue includes sections like:
-board-ready summary
-comp / leverage reset
-top deal-pricing events
-deal-structure watchouts
-outreach / screening priorities
-precedent table
-mispricing flag

If you want the 4-week beta, just drop your email on the sample page. (And if you know any BD professionals who might be interested feel free to forward this to them).

[PDUFA Pulse @PDUFA_Pulse]

$CING Receives CRL for CTx-1301 NDA for the treatment of ADHD.

[PDUFA Pulse @PDUFA_Pulse]

@PulpLibrarian Not at all, video synthesis is alive and well.

[PDUFA Pulse @PDUFA_Pulse]

$VERA is now close enough to be on the radar.

Atacicept has a July 7 PDUFA in IgA nephropathy.

Priority Review + Breakthrough designation + proteinuria-driven Phase 3 package.

Not this week’s hard clock, but it belongs in the field of view.

[PDUFA Pulse @PDUFA_Pulse]

$IONS is one of the more interesting late-June setups.

TRYNGOLZA is already approved in FCS. The pending review is severe hypertriglyceridemia.

That matters because sHTG is a much broader commercial opportunity than the original ultra-rare launch indication.

[PDUFA Pulse @PDUFA_Pulse]

Late June board:

$ARQT — pediatric ZORYVE label expansion
$LNTH — SSTR+ NET imaging
$IONS — TRYNGOLZA severe HTG expansion

Three different flavors of FDA risk:
label expansion, diagnostic CMC/manufacturing, broader commercial opportunity.

[PDUFA Pulse @PDUFA_Pulse]

The next clean FDA setup on my board is $SPRO.

Tebipenem HBr has a June 18 PDUFA for cUTI including pyelonephritis.

The key angle: potential first oral carbapenem option.

That matters because the carbapenem conversation has historically been IV-heavy.

[PDUFA Pulse @PDUFA_Pulse]

The FDA board reset this week:

$IRWD ✅ approved
$MNKD ✅ approved
$CING ⏳ still open after Sunday PDUFA
Next queue:
$CING → $SPRO → $ACHV → $ARQT / $LNTH → $IONS → $VERA

Cleaner board. Not a quiet one.

[Daphne Zohar @daphnezohar]

A few people have asked me to comment on this article & the topic of US biotech competitiveness vis-à-vis China. I agree w/ Peter & Tess that expanding the COINS Act to biotech would have negative consequences. Risks handing global leadership & profits to EU competitors while doing little to slow China’s dominance. Also agree that we must protect critical supply chains/manufacturing from a national security perspective.

While COINS for biotech is a bad idea, we need proactive legislation to strengthen US biotech innovators. Targeted measures could include tradable/refundable R&D tax credits (noted in article) & priority review vouchers (@rtnarch), NOL reforms (amending Section 382), enhanced data exclusivity for genuine first-in-class assets & patent reform. These could level the playing field for US innovators without the protectionism & restrictions that would raise costs & slow patient access to new medicines

[PDUFA Pulse @PDUFA_Pulse]

FDA quietly dropped a meaningful oncology-development signal.

New draft guidance would reduce unnecessary animal testing for certain cancer drugs, including cases where one relevant species, or non-animal evidence, may be enough.

That matters because “faster drug development” increasingly means changing the preclinical burden, not just speeding reviews.

[PDUFA Pulse @PDUFA_Pulse]

$MNKD approval.

FDA cleared Afrezza for pediatric use in diabetes, giving children/adolescents 6+ a needle-free mealtime insulin option.

The regulatory risk is now answered.

The next test is commercial: prescriber comfort, pulmonary screening, payer access, and whether convenience can change Afrezza uptake.

[PDUFA Pulse @PDUFA_Pulse]

$CING has the awkward kind of PDUFA date: May 31 lands on Sunday.

CTx-1301 is not a “does dexmethylphenidate work?” story.

It is a 505(b)(2) / timed-release / CMC response story.

If the date bends, manufacturing is the first place to look.

[PDUFA Pulse @PDUFA_Pulse]

$REPL is the most important FDA-process story today.

RP1 received two CRLs.

Now Replimune says FDA has aligned on a resubmission path and will treat the new filing as urgent.

This is not “approved.”

It is a potential regulatory about-face watch.

[PDUFA Pulse @PDUFA_Pulse]

$CING - CTx-1301 is the kind of FDA setup where the headline can mislead.

-ADHD drug.
-Known active ingredient.
-505(b)(2) path.
-Timed-release differentiation.

But the real risk is not the ADHD market.
It is whether FDA is satisfied with CMC, manufacturing, and pre-approval inspection issues by the May 31 clock.
Different question.

[PDUFA Pulse @PDUFA_Pulse]

$MNKD - Tomorrow’s Afrezza decision is still not a simple pediatric expansion watch.

-Yes, it is an already-approved adult product.
-Yes, the commercial hook is obvious: needle-free mealtime insulin for ages 4–17.

But the regulatory tension remains:
-Full ITT missed noninferiority.

Sensitivity case carries the approval argument.

That is the whole trade.

[PDUFA Pulse @PDUFA_Pulse]

$SPRO - Tebipenem HBr still looks like one of the more consequential June FDA decisions.

📅PDUFA: Jun. 18.

Why it matters:
-Potential first oral carbapenem for cUTI, including pyelonephritis.

That isn't only an antibiotic approval story.

It is an IV-to-oral conversion story in a hospital-heavy category.

[PDUFA Pulse @PDUFA_Pulse]

$UNCY- Unicycive is quietly becoming one of the cleaner late-June resubmission watches.

OLC PDUFA: Jun. 29.
-This is a Class II resubmission after a prior CRL tied to manufacturing / vendor compliance.

The key issue is not whether hyperphosphatemia is a real market.

It is whether FDA is now satisfied with the package behind the product.

[PDUFA Pulse @PDUFA_Pulse]

$OTLK - The Outlook story changed materially this week.

A CRL / dispute-resolution setup is now a June resubmission setup.

FDA’s Office of New Drugs concluded substantial evidence of effectiveness has been established for Lytenava in nAMD.

That does not equal approval.

But it changes the next question from “is the file dead?” to “how clean is the resubmission?”

[PDUFA Pulse @PDUFA_Pulse]

$ARVN - Vepdegestrant is a good example of why the PDUFA date is not always the event date.

FDA approved VEPPANU more than a month ahead of the June 5 clock.
-First FDA-approved PROTAC.

But the stock story is more complicated:
-Approval validates the modality.
Commercial economics still decide the trade.

[PDUFA Pulse @PDUFA_Pulse]

$ONC - Sonrotoclax already resolved before the May 31 clock.

FDA granted accelerated approval for R/R mantle cell lymphoma after at least two prior lines, including a BTK inhibitor.

The live question now shifts:
-Not “will FDA approve?”
-But how much commercial space exists behind BTK failure, and how confirmatory-risk gets priced.